Clinical Trial

The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 12, 2021 (before its estimated August 31, 2023 completion). Its status may not reflect the trial's current state.
Summary
The management of HR-positive, HER2-negative metastatic breast cancer includes endocrine monotherapy or combination regimens, both with benefit diminishing as resistance develops. Nowadays, various studies have demonstrated that estrogen interacts with many angiogenic pathways and is an important mechanism for resistance leading to the question of whether combination with antiangiogenesis and antiestrogen therapies could be an appropriate therapeutic modality. Anlotinib is a novel multi-target tyrosine kinase inhibitor that effectively inhibit VEGFR, FGFR, PDGFR, c-KIT, c-MET and RET. Previous studies have proven the efficacy of both anlotinib monotherapy and combination regimens in advanced breast cancer. This phase II study aims to preliminarily evaluate the efficacy and safety of anlotinib combined with endocrine therapy.
Trial Details
NCT Number NCT05075512
Lead Sponsor Zhejiang Cancer Hospital
Conditions Breast Neoplasm Female
Enrollment 40 participants
Start Date 2021-09-01
Primary Completion 2023-08-31 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2021-10-12